Adolescent Medicine
Breastfeeding/Human Milk
Immunizations/Delivery
Infectious Diseases
Neonatology
Pharmacology and Therapeutics
Public Health
Well Newborn
.jpg "Pablo Sanchez, MD photo")
Pablo Sanchez, MD
Professor of Pediatrics
Pediatrics
Nationwide Children's Hospital -OSU
Columbus, Ohio, United States
Session
Description: As of September 28, 2022, a total of 25,341 monkeypox cases have been reported in the United States. Although predominantly affecting men who have sex with men, pediatric cases have occurred. In addition, cases in pregnant women may result in fetal and neonatal infection. This Hot Topic session will highlight the current epidemiology and the management of exposed and/or infected newborns, infants, children, and adolescents. Monkeypox should be considered when children or adolescents present with a rash that is consistent with the disease, especially if epidemiologic criteria are present. Young children, children with eczema and other skin conditions, and children with immunocompromising conditions may be at increased risk of severe disease. Treatment should be considered on a case-by-case basis for children and adolescents with suspected, probable, or confirmed monkeypox who are at risk of severe disease or who develop complications of monkeypox. Tecovirimat is the first-line medication to treat monkeypox, including in children and adolescents. Children and adolescents with close contact to people with suspected, probable, or confirmed monkeypox may be eligible for post-exposure prophylaxis (PEP) with vaccination, immune globulin, or antiviral medication.
Speaker: Faisal S. Minhaj, PharmD, MPH – Centers for Disease Control and Prevention
Speaker: Anne Kimball, MD, MPH (she/her/hers) – Centers for Disease Control and Prevention